ubiquitin protein ligase (VHL) 6 
inactivation (3 ).
A number of additional molecular changes have been recently reported in ccRCC at the mRNA, protein, and microRNA (miRNA) levels; although these studies represent a step forward, they focus on only one type of molecule, whereas cancer development necessitates an interaction between different levels of molecular changes. More recently, "integrated genomics" holds the promise of a much better understanding of the pathogenesis of ccRCC through analyzing the interaction between the different levels of molecular changes. Furthermore, integrated analyses could help in overcoming the problem of tumor and patient heterogeneity, a recently recognized challenge in cancer research (4 ) . A number of recent studies have shown the great advantages of the integrating approach in RCC (5 ) (6, 7 ) .
The goal of this study was to obtain greater knowledge of the complex biological background of kidney cancer tumor development by using a systems biology approach to integrate molecular changes of ccRCC at the mRNA, miRNA, and protein expression levels to identify novel pathways and new pathogenetic factors that can be of clinical utility as prognostic biomarkers or potential therapeutic targets.
Materials and Methods

PATIENT COHORTS
The discovery set included high-throughput gene, miRNA, and protein expression data from 593 ccRCC and 389 normal kidney samples. The first validation set comprised the Cancer Genome Atlas data of 470 ccRCC and 69 normal kidneys (mRNA sequencing data) and 499 ccRCC and 66 normal samples (miRNA sequencing data). For the second validation set, we constructed a tissue microarray of 383 primary ccRCC, and 85 matched normal tissues (Fig. 1A) .
Details of the applied data sets, RNA isolation, quantitative PCR, and bioinformatics analysis are presented in Fig. 1 , B and C, and the Supplementary Materials and Methods file and Supplementary Table 1 in the Data Supplement that accompanies the online version of this report at http://www.clinchem.org/content/ vol60/issue10.
CELL PROLIFERATION, MIGRATION, AND INVASION ASSAYS
FOLLOWING siRNA TRANSFECTION
The primary 786-O and metastatic CAHN and Caki-2 kidney cancer cell lines were purchased from American Type Culture Collection. Cells were transfected with 1 of 2 different Locked Nucleic Acid® small interfering RNAs (siRNAs), an siRNA against KIAA0101 (Silencer Select s18861, s18863) (30 nmol/L) (Life Technologies), or a negative-control siRNA (30 nmol/L) using Lipofectamine RNAiMAX (Life Technologies). Transfections were optimized by BLOCK-it fluorescent oligo (Life Technologies). Gene knockdown was verified by quantitative PCR using the previously published primers 5Ј-AGGTTGTCCCCTAAAGATTCTG-3Ј and 5Ј-CAGGTTGCAAAGGACATGC-3Ј (8 ) after RNA isolation (miRNAs kit, Qiagen) and by Western blot using a published mouse monoclonal antibody against KIAA0101 (H00009768-M01; Abnova) (9 ) . Cell proliferation/viability was controlled by WST-1 cell proliferation reagent (Roche Applied Science) according to the manufacturer's protocol, and cell number was counted after trypsinization. Cell behavior was investigated by migration and invasion assays (BD-Bio coat), as previously described, on 8.0-m chambers (10 ). 6 Human genes: VHL, Von Hippel-Lindau tumor suppressor, E3 ubiquitin protein ligase (von Hippel-Lindau tumor suppressor, E3 ubiquitin protein ligase, is involved in the ubiquitination and degradation of hypoxia-inducible factor (HIF). The germline mutation on VHL is a cause of von Hippel-Lindau syndrome); CCND1, cyclin D1 (cyclin D1 controls cell cycle by regulating CDK4 and CDK6 activity which is required for G1/S transition); CDKN2A, cyclin dependent kinase inhibitor 2A (cyclin dependent kinase inhibitor 2A regulates cell cycle G1 progression by inhibiting CDK4 kinase. It also stabilizes p53); ETS1, v-ets avian erythroblastosis virus E26 oncogene homolog 1 (v-ets avian erythroblastosis virus E26 oncogene homolog 1 is a transcription factor that controls the expression of numerous genes involved in stem cell development, cell senescence and death, and tumorigenesis); ISG15, ubiquitin-like modifier (ISG15 ubiquitin-like modifier, the product of this gene is an ubiquitin-like protein that is conjugated to intracellular target proteins upon activation by interferon-alpha and beta); KIAA0101, KIAA0101 (also called PAF (PCNA-associated factor, regulates DNA repair during DNA replication); FBXO21, F-box protein 21 (F-box protein 21 is a member of the F-box protein family and constitutes a subunit of ubiquitin protein ligase complex, which functions in phosphorylation-dependent ubiquitination); GRHL2, grainyhead like-2 (grainyhead like-2, a transcription factor, plays a role in development, and its defect leads to sensorineural deafness); TCF4, transcription factor 4 (transcription factor 4, a basic helix-loophelix transcription factor that is broadly expressed, plays an important role in nervous system development); ZEB1, zinc finger E-box binding homeobox 1 (zinc finger E-box binding homeobox 1 is a transcription factor that among other functions represses E-cadherin promoter and induces an epithelialmesenchymal transition. It promotes tumorigenicity by repressing stemnessinhibiting miRNAs); CCND2, cyclin D2 (cyclin D2 forms a complex with and regulates CDK4 and CDK6 in cell cycle G1/S transition. In a complex with CDK4 it phosphorylates and inhibits retinoblastoma 1 (RB1) protein to control the restriction point of the cell cycle); AHR, aryl hydrocarbon receptor (aryl hydrocarbon receptor is an intracellular ligand activated receptor and transcription factor, and regulates xenobiotic-metabolizing enzymes expression); SMAD2, SMAD family member 2; SMAD3, SMAD family member 3 SMAD family members are intracellular signal transducers and mediate the signal of TGF-␤. SMAD2 and -3 are receptor-regulated SMADs activated by TGF-␤ and activin type 1; then, in a complex with other molecules, they bind the SBE (SMADbinding elements) of DNA sequences; CDK6, cyclin-dependent kinase 6; SOX9, SRY (sex determining region Y)-box 9; CXCR4, chemokine (C-X-C motif) receptor 4 (the receptor for the C-X-C chemokine CXCL12/SDF-1, plays roles in many diverse cellular functions, including embryogenesis, immune surveillance, inflammation response, tissue homeostasis, and tumor growth and metastasis); LAMC1, laminin, gamma 1; ITGB1, integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes MDF2, MSK12); FOS, FBJ murine osteosarcoma viral oncogene homolog (a transcription factor and can dimerize with proteins of the JUN family, thereby forming the transcription factor complex AP-1. It has been implicated as a regulator of cell proliferation, differentiation, and transformation). 
Results
PATHWAY ANALYSIS
First, we identified mRNAs, proteins, and miRNAs that are commonly differentially expressed between ccRCC and normal kidney tissues (see online Supplementary  Tables 2 and 3) . After performing pathway analysis, we found that the most commonly altered signaling were metabolic pathways related to glucose metabolism ("glycolysis"), fatty acid-retinoic acid ("LXR/RXR activation"), and amino-acid metabolism ("valine degradation") (see online Supplementary Table 4) . We also identified "renal cell cancer," "hypoxia signaling," and "angiopoietin signaling" among the significant pathways, and "cellular movement" and "cell death and survival" on the basis of the gene expression profile, with the functional terms "renal cancer," "kidney development," "angiogenesis," "migration and proliferation of vascular endothelial cells," and "vascularization" among BioFunction categories. "AHR signaling" was also identified as significant ( Fig. 2 ; also see online Supplementary Fig. 1 for a version of this image that can be enlarged). This pathway is involved in xenometabolism, cell cycle, differentiation, and apoptosis, but has not yet been linked to ccRCC pathogenesis; thereby we selected it for further validation.
NETWORK ANALYSIS
We built an interaction network using the most significant molecules. This network is based on an unbiased approach that relies only on molecular interactions and thus differs from pathway analysis that performs gene set enrichment on a predefined gene set. The network structure is formed of basic elements (mRNAs or proteins), designated nodes, and the physical interactions or relationships between these nodes (edges) (11 ) . Interactions are directionally based on their type (such as activation and inhibition). The relationships between different members are predicted by computational algorithms and/or literaturedocumented experimentally validated interactions (e.g., protein-protein, protein-DNA, RNA-miRNA). The highest-degree nodes based on the number of interactions are generally defined as hubs. In our ccRCC network, 5 nodes were determined as hubs (cyclin D1 ). In the functional annotation of the network members, we found "proliferation of kidney cells" and "angiogenesis" categories to be significant (data are not shown).
Based on directional interactions, a network hierarchy contains 3 (or more) layers of nodes (see online Supplementary Fig. 2A ). Genes in the "top" layer(s) are considered to be the master regulators of the network because they are not affected by other nodes, and these genes act as regulators of all others, and as such, they should influence the whole network through their downstream targets. The second, "core" layer(s) usually contain the majority of the hubs, which determine the basic structure of the network. This layer plays a central role in the regulation of signal propagation and modulation (the signal can be enhanced, attenuated, or buffered). Genes in the third, "bottom" layer(s) are directly regulated effector molecules (12 ) . The top-layer genes are potential drug targets, being "directors" of the network and having only a few further connections; therefore, targeting of these molecules should be associated with fewer side effects (13 ) . Regarding our network among top members, the only individual genes were F-box protein (FBXO21) and grainyhead like-2 (GRHL2), whereas the other members were molecular groups/families (Fig. 3) , and the core layer was the most abundant layer, containing all of the hubs.
miRNA CONTRIBUTION TO ccRCC PATHOGENESIS
Integrating another level of regulation, we subsequently identified tissue-specific miRNAs that are predicted to target network members (see online Supplementary Table 5 ). The miRNAs miR-124, miR-139-5p, and miR-204-5p had the most important effect on the expression of network members, with each of them targeting 4 different transcripts (see online Supplementary Fig. 2B ). Transcription factor 4 (TCF4), zinc finger E-box binding homeobox 1 (ZEB1), and cyclin D2 (CCND2) were the genes found to be most influenced by these miRNAs.
We also identified 11 miRNAs that are predicted to target the AHR signaling pathway, among these, miR-203-3p and miR-124 -3p can target the aryl hydrocarbon receptor (AHR) gene itself (Fig. 2) . 
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VALIDATION OF GENE DEREGULATION IN ccRCC
For validation of our results, we selected 3 critical genes, AHR, which is a major component of AHR signaling that was significantly affected in ccRCC in our pathway analysis, GRHL2, which is located in the top level of the network, and KIAA0101, which is among the highest-degree hubs in our network.
In the first step, we used the Cancer Genome Atlas (TCGA) data set to assess gene expression at the mRNA levels between normal and cancerous tissues. AHR and KIAA0101 expressions were significantly higher in ccRCC than in normal kidney [fold change, 1.72 (P Ͻ 0.0001) and fold change, 5.2 (P Ͻ 0.0001)] (Fig. 4 , A and K); and GRHL2 downregulation was confirmed in ccRCC with a 16.1-fold change (P Ͻ 0.0001) (Fig. 4F) . We also validated the downregulation of miR-124, miR-204 -5p, miR-139 -5p, miR-141, and miR-199a and the upregulation of miR-23a in kidney cancer compared to normal tissue (see online Supplementary  Fig. 2C ).
We next investigated the differential expression of these genes at the protein level using immunohistochemical analysis on our individual sample set using a TMA format. As shown in Fig. 4 , D-E, and online Supplementary Table 6 , expression of AHR was upregulated in 75% of patients in comparison to normal tissue. Expression of GRHL2 was found to be significantly downregulated in 90% of cancerous samples compared to normal tissue (Fig. 4I ). KIAA0101 expression was higher in ccRCC than in normal counterparts in 56% of cases (P ϭ 0.003) ( Fig. 4N ; also see online Supplementary Table 6 ). We also confirmed KIAA0101 upregulation in ccRCC using Western blot analysis (Fig. 4M ).
DIFFERENTIAL EXPRESSION OF AHR, GRHL2, AND KIAA0101 IN ccRCC COMPARED TO NORMAL KIDNEY TISSUE
ROC analysis showed the potential utility of AHR to distinguish cancer from normal kidney tissues on the basis of mRNA expression levels [area under the ROC curve (AUC) 0.825 with 80% sensitivity and 80% specificity at a cutoff of expression of 1413.4 (read number)] (Fig. 4B) . Also, the lower mRNA expression of GRHL2 was highly specific for the tumors [AUC, 0.963 (P Ͻ 0.0001); cutoff of expression, 130.2 (read number)] (Fig. 4G) . KIAA0101 was also found to be a potential diagnostic biomarker (AUC, 0.956, P Ͻ 0.001) [at cutoff of expression 30.9 (read number), 94.4% sensitivity and 91.3% specificity] (Fig. 4L) .
THE IDENTIFICATION OF POTENTIAL PROGNOSTIC MARKERS FOR ccRCC
We assessed the prognostic significance of AHR, KIAA0101, and GRHL2 in ccRCC at both mRNA and protein levels.
GRHL2 AS A PROGNOSTIC MARKER IN ccRCC
Lower mRNA expression levels for GRHL2 were associated with significantly better survival (Fig. 4H) . GRHL2 protein expression in cancer tissues is positively associated with tumor grade (P Ͻ 0.001) (see online Supplementary Table 7 ) and with tumor size (GRHL2-positive staining in 19% of tumors Ͻ4 cm vs 48% in those Ն4 cm, P ϭ 0.001) (Supplementary Table Significant numbers of members of this pathway were frequently reported as significantly dysregulated in ccRCC, as shown in the color legend. The color intensity corresponds to the number of studies showing the dysregulation. After ligand binding, AHR translocates to the nucleus, where it transactivates/represses several genes. This figure can be also found as online Supplementary Fig. 1 , where it can be enlarged. NF-B, nuclear factor B; IL-1, interleukin 1; TNF, tumor necrosis factor; HSP90, heat shock protein 90; XAP2, X-associated protein 2; TEBP, telomere end binding protein; Src, Src protein; ESR1, estrogen receptor 1; Rb, retinoblastoma protein; ATM, ataxia telangiectasia mutated protein; ATR, ataxia telangiectasia and Rad3-related protein; CDK, cyclin dependent kinase; AHRR, aryl hydrocarbon receptor repressor; ARNT, AhR nuclear translocator; MDM2, mouse double minute 2 homolog; ChK2, checkpoint kinase 2; RelA, v-rel avian reticuloendotheliosis viral oncogene homolog A; ERK, extracellular signal-regulated kinase; JNK, c-Jun amino-terminal kinase; NR2F1, nuclear receptor subfamily 2, group F, member 1; NR0B2, orphan nuclear receptor DAX-1; SMRT, silencing mediator of retinoic acid and thyroid hormone receptor; NCOA7, nuclear receptor coactivator 7; NEDD8, neural precursor cell expressed, developmentally down-regulated 8; RIP140, receptor-interacting protein 140; DRE, DNA replication-related element; XRE, xenobiotic response element; E2F1, E2F transcription factor 1; RAR, retinoic acid receptor; RXR, retinoid X receptor; RARE, RAR binding element; RXRE, RXR binding element; TGM2, transglutaminase 2; Arf, ADP-ribosylation factor; Apaf1, apoptotic peptidase activating factor 1; c-Myc, c-v-myc avian myelocytomatosis viral oncogene homolog; p27Kip1, cyclin-dependent kinase inhibitor 1B (p27, Kip1); p21Cip1, cyclindependent kinase inhibitor 1A (p21, Cip1); BAX, BCL2-associated X protein; Fas, fatty acid synthase; CYP1B1, cytochrome P450, family 1, subfamily B, polypeptide 1; ALDH, aldehyde dehydrogenase; NQO, NAD(P)H:quinone acceptor oxidoreductase; GST, glutathionine S-transferase; NRF2, nuclear factor erythroid 2-related factor; ARE, antioxidant response element.
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In univariate analysis, GRHL2 protein expression was associated with higher chances for disease relapse [hazard ratio (HR), 3.81, 95% CI, 1.54 -9.42, P ϭ 0.004] ( Table 1 ). The GRHL2 protein expression association with shorter overall survival, although positive, did not reach statistical significance (HR, 2.79; 95% CI, 0.531-14.67; P ϭ 0.225). In multivariate analysis, GRHL2 retained its prognostic utility after controlling for grade and stage (HR, 3.47; 95% CI, 1.32-9.15; P ϭ 0.012). Kaplan-Meier survival analysis showed that GRHL2-positive patients had significantly lower disease-free survival than those who were GRHL2 negative (P ϭ 0.002) (Fig. 4J) . No association was found between GRHL2 expression and overall survival (data not shown).
KIAA0101 AS A PROGNOSTIC MARKER IN ccRCC
KIAA0101 had significant influence on prognosis at the mRNA level: higher expression was associated with worse overall survival (P Ͻ 0.0003) (see online Supplementary Fig. 3A) . On the protein level, no statistically significant association was found between KIAA0101 expression and tumor grade (see online Supplementary Table 7 ). Univariate analysis showed that KIAA0101-positive patients had worse disease-free survival (HR, 3.64; 95% CI, 2.09 -6.31, P Ͻ 0.001) (Table 1). Although there was an association between KIAA0101 and worse overall survival, this was not statistically significant (P ϭ 0.094) ( Table 1 ). In the multivariate analysis, KIAA0101 retained its independent prognostic significance after controlling for tumor size and grade (HR, 2.76, P Ͻ 0.001) or grade and stage (HR, 2.73, P ϭ 0.002). Kaplan-Meier survival analysis indicated that KIAA0101-positive patients had reduced disease-free survival (P Ͻ 0.001) (Fig. 4O ). Those patients also had lower overall survival, although this was not statistically significant (P ϭ 0.087) (see online Supplementary Fig. 3B ).
AHR AS A PROGNOSTIC MARKER IN ccRCC
At the mRNA level, higher expression of AHR was associated with better overall survival (Fig. 4C) . AHR protein expression in cancer tissues was negatively associated with tumor grade (P ϭ 0.047) (see online Supplementary Table 7) . Univariate and multivariate analyses showed no significant association Hubs (nodes with the most significant number of interactions) are bolded. After the hierarchy of the nodes was determined on the basis of their directed relationships, nodes were categorized into top, core, and bottom levels. See text for more discussion. acad, acyl-CoA dehydrogenase; SLC16A1, solute carrier family 16 (monocarboxylate transporter), member 1; SHMT2, serine hydroxymethyltransferase 2 (mitochondrial); SUCLG2, succinate-CoA ligase, GDP-forming, beta subunit; APOM, apolipoprotein M; SLIT2, slit homolog 2 (Drosophila); CTSH, cathepsin H;HSPA6, heat shock 70 kDa protein 6; RNF213, ring finger protein 213; DEGS1, delta(4)-desaturase, sphingolipid 1; FAM171A1, family with sequence similarity 171, member A1; FHIT, fragile histidine triad; RALYL, RALY RNA binding protein-like; LMO3, LIM domain only 3 (rhombotin-like 2); RUNX3, runt-related transcription factor 3; CSTA, cystatin A (stefin A); GLT25D1, glycosyltransferase 25 domain containing 1; CEP170, centrosomal protein 170kDa; GATA3, GATA binding protein 3; INSIG2, insulin-induced gene 2 protein; CDKN1C, cyclin-dependent kinase inhibitor 1C; DSP, desmoplakin; IFI44, interferon-induced protein 44; DDX41, DEAD (Asp-Glu-Ala-Asp) box polypeptide 41; ZC3HAV1L, zinc finger CCCH-type, antiviral 1-like; PFKP, phosphofructokinase, platelet; ALDOA, aldolase A, fructose-bisphosphate; KHK, ketohexokinase (fructokinase); LYZ, lysozyme; IGF2BP2, insulin-like growth factor 2 mRNA binding protein 2; C21orf33, chromosome 21 open reading frame 33; LDHB, lactate dehydrogenase B, PKM, pyruvate kinase; AZGP1, alpha-2-glycoprotein 1, zinc-binding; WFDC2, WAP four-disulfide core domain protein 2; PHGDH, phosphoglycerate dehydrogenase; PLOD3, procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3; LTF, lactotransferrin; IKZF1, IKAROS family zinc finger 1 protein; Ctbp, C-terminal binding protein; ACLY, ATP citrate lyase; MYOF, myoferlin; EGLN3, egl-9 family hypoxia-inducible factor 3; ELF4, E74-like factor 4 (ets domain transcription factor); ANXA3, annexin A3; IKBIP, Inhibitor of nuclear factor kappa-B kinaseinteracting protein, partial; CP, ceruloplasmin (ferroxidase); MPPED2, metallophosphoesterase domain containing 2; PRAP1, proline-rich acidic protein 1; STRA6, stimulated by retinoic acid 6; LRP2, low density lipoprotein receptor-related protein 2; MEST, mesoderm specific transcript; SLC39A4, solute carrier family 39 (zinc transporter), member 4;PMEPA1, prostate transmembrane protein, androgen induced 1; ABCC1, ATP-binding cassette, sub-family C (CFTR/MRP), member 1; HPGD, hydroxyprostaglandin dehydrogenase 15-(NAD); RHOBTB3, rho-related BTB domain-containing protein 3; RBP4, retinol binding protein 4, plasma; PLAT, plasminogen activator, tissue; ANPEP, alanyl (membrane) aminopeptidase; MPZl2, Myelin protein zero-like protein 2; MELK, maternal embryonic leucine zipper kinase; TBXAS1, thromboxane-A synthase; ARL4C, ADPribosylation factor-like 4C; CMTM3, CKLF-like MARVEL transmembrane domain-containing protein 3; SERPINE1, serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1. with either progression-free or overall survival (data not shown).
THE EFFECT OF KIAA0101 ON RCC TUMOR CELL BEHAVIOR
Because KIAA0101 was one of the most significant hubs (node having the most connection with other members) in our network, we explored its potential effect on ccRCC tumor cell behavior using cell-line models. Loss-of-function experiments were done using KIAA0101-specific siRNA (see online Supplementary Fig. 3 , C-E). There was no significant effect of KIAA0101 knockdown on cell proliferation and viability in the primary 786-O and the metastatic ACHN and Caki-2 kidney cancer cell lines (Fig. 5A) . However, silencing KIAA0101 significantly reduced cell migration and invasion by 39.8% and 78.8% compared to the nontargeting control siRNA (P Ͻ 0.05) (Fig. 5 , B-C).
Discussion
In this present work we performed a uniquely comprehensive integrative analysis and built a new gene interaction network on the basis of large publicly available data sets assembled from 28 publications, comprising a 3-prong approach with high-throughput mRNA, miRNA, and protein expression profiles of 593 ccRCC and 389 normal kidney samples. For this aim we used Ingenuity Pathway Analysis (IPA) software that employs a curated database [the IPAKB (IPA Knowledge Base)], which contains scientific data from numerous journal articles, textbooks, and other data sources and canonical pathways, similarly to GeneGo or Pathway Studio (14 ) . These databases/software programs can help to translate omics data (e.g., mRNA, miRNA microarray, metabolic, proteomics) by pathway and network analysis using specific directional interactions between protein-protein, protein-DNA, and protein-RNA, drug targeting, and bioactive molecules and their effects. The main power of this analysis is the large number of samples, the combination of different patient sets and platforms, and the use of 2 different validation sets, in addition to the discovery cohort. Literature data suggest that combination of results from similar biological experiments analyzed on different microarray platforms gives a more complete transcriptomic profile and is more informative than considering them individually (15 ) . Is has also been suggested that this kind of combination of studies, by increasing the number of replicates, adds robustness to the experimental design and limits undesired effects and bias in expression profiles, especially when comparing 2 or more platforms" (16 ) . Additionally, the present work relies more on mRNA than protein data, because the numbers of identified proteins of the included studies are relatively smaller than those for mRNA data because of the limitations of the high-throughput protein expression analysis methods used (see online Supplementary Table 1). With this approach we tried to identify those pathways which were significant in the most independent studies as common features, rather than to analyze tumor heterogeneity among individual samples. Our findings are in keeping with previous data indicating that metabolic pathways are critical in ccRCC pathogenesis (17 ) , and we showed that AHR signaling is altered in ccRCC. We identified and validated AHR as an overexpressed gene that is regulated by the underexpressed miR-124 in ccRCC, an interaction that already has been experimentally validated in other tumors (18 ) . AHR can mediate either tumor-promoting or -inhibiting effects. In mammary tumors, high levels AHR were detected (19 ) . In addition, overexpression of AHR resulted in increased hepatic and stomach tumor development, and its knockdown reduced tumor growth and metastasis. In contrast, AHR null mice have hyperplastic phenomena (hyperkeratosis of the skin, hyperproliferation of hair follicles, hyperplasia in the gastric pylorus, hyperproliferation of portal blood vessels) and develop liver and lung adenocarcinoma (20 ) . Active AHR expression led to growth inhibition and apoptosis, and caused cell-cycle arrest (21, 22 ) . It was also reported that AHR activation has a promigratory effect in epithelial cells and enhances cancer invasion in urothelial cancer (23 ) . AHR can also represent a therapeutic target. Callero et al. reported that activating AHR with an agonist inhibited cell growth in a dose-dependent manner in RCC cell lines (24 ) . It was also found that sunitinib, a tyrosine kinase inhibitor used for metastatic ccRCC, induced CYP1A1 expression through AHR in breast cancer (25 ) . Aminoflavone, which has an antiproliferative effect on human breast cancer cells mediated by AHR, is also applied in clinical trials as a new anticancer drug. It was found to inhibit cell growth and to induce apoptosis in several but not all renal cancer cell lines as well (24 ) .
By characterizing the ccRCC disease network, we identified the most significant molecules in the pathogenesis as hubs (KIAA0101, CCND1, ETS1, CDKN2A). Among these, CCND1 and ETS1 were already linked to kidney cancer. ETS1 was found to correlate with microvascular density in ccRCC (26 ) . We found that GRHL2 was underexpressed in tumors compared to normal kidney both for mRNA and protein levels and can be a potential prognostic marker based on immunostaining. GRHL2 is a transcription factor playing roles in development, regulation of epithelial mesenchymal transition (EMT), and restoring the sensitivity to anoikis (27 ) . GRHL2 overexpression was detected in several cancers; however, in certain subclasses of breast cancer, GRHL2 was downregulated (27, 28 ) . This dual, context-dependent effect of GRHL2 might be explained by operation through transforming growth factor ␤ (TGF-␤) signaling, which also has both tumorpromoting and -suppressing effects in a contextdependent manner. It was shown that GRHL2 interferes with TGF-␤ signaling by repressing the ZEB1 promoter and by interfering with SMAD family member 2 (SMAD2)-and SMAD family member 3 (SMAD 3)-mediated transcriptional activation (27 ) . Its overexpression suppressed primary tumor growth in xenograft assay and tumor cells sensitized to chemotherapyinduced cytotoxicity (27 ) . In breast cancer, GRHL2 was found to be downregulated in the context of TGF-␤/EMT-driven tumor types and its loss was associated with a mesenchymal phenotype (27 ) ; thereby, GRHL2 was considered as an "oncogenic restriction point" (27 ) . The role of GRHL2 downregulation in ccRCC has not been investigated, but its target, ZEB1, which is a direct suppressor of GRHL2, is overexpressed in kidney cancer. The GRHL2 targets miR-200a and-b are underexpressed in ccRCC samples (29 ) , which supports the role of GRHL2 in ccRCC. These, and GRHL2 being a top-layer gene in the network, suggest that restoring of the function of GRHL2 (including its downstream targets) may be a new, potentially therapeutic direction in addition to being a potential diagnostic marker. KIAA0101 encodes a PCNA (proliferating cell nuclear antigen)-associated factor, also referred to as PAF15 (proliferating cell unclear antigen-associated factor). The KIAA0101 protein plays a role in controlling cellcycle progression through affecting DNA replication. Its role in the cell cycle and DNA damage response was also described (30 ) . The APC/C (cell cycle anaphasepromoting complex/cyclosome) controls degradation of substrate proteins, such as KIAA0101, at mitotic exit and throughout the G1 phase (30 ) . This may explain the relationship between high KIAA0101 expression and cancer. KIAA0101 was found to be overexpressed in several malignancies, such as breast, gastric, hepatocellular, adrenal, lung, and pancreatic carcinoma. We found that KIAA101 was significantly overexpressed at both the mRNA and protein levels in ccRCC, similarly to other cancers. In line with previous reports, we found that knockdown of KIAA0101 led to reduced migration and invasion ability of kidney cells but did not affect the cell proliferation similarly to adrenal cancer (31 ) . In several cell types, proliferation and migration/invasion are distinct, supporting the "go or grow" hypothesis (32 ) . Our results suggest that KIAA0101 is involved in malignant behavior and development of metastasis of ccRCC cells rather than tumorigenesis. We also showed that the increased expression of KIAA0101 protein was positively associated with poor prognosis, in agreement with recent reports in other tumors (33 ) . Interestingly, circulating KIAA0101 mRNA has also been shown to be a predictive marker for hepatic cancer (33 ) .
MiR-124, miR-139, and miR-204 were downregulated and we considered them to be the most critical miRNAs influencing our ccRCC network having 4 targets each. MiR-124 was characterized as tumor suppressor in several tumor types. It has an essential role in differentiation of neural stems cells and neural progenitor cells (34 ) , and its downregulation promotes growth, invasiveness, and metastasis (35 ) by targeting laminin, gamma 1 (LAMC1), integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes MDF2, MSK12) (ITGB1), cyclin-dependent kinase 6 (CDK6), and SRY (sex determining region Y)-box 9 (SOX9) (36 ) . Similarly, miR-204 loss enhanced migration and stem cell phenotype in vivo (37 ) . MiR-139 expression was shown to differ between different kidney cancer subtypes (38 ) and was also linked to metastasis and prognosis in ccRCC (39 ) . In our network, miR-139 targets ETS1, TCF4, ZEB1, and CCND2. This miRNA was found to be downregulated in other cancers and target chemokine (C-X-C motif) receptor 4 (CXCR4) and FBJ murine osteosarcoma viral oncogene homolog (FOS) (40, 41 ) . All 3 miRNAs (miR-124, miR-204, and miR-139) target TCF4 and CCND2. The overexpressed ETS1 and ZEB1 are both targeted by 2 of these three miRNAs. On the basis of their role in the RCC disease network, we propose that these 3 miRNAs have the most important role in ccRCC pathogenesis.
In conclusion, using an integrative systems biology approach, we determined that AHR signaling, and a number of critical molecules, including GRHL2 and KIAA0101, are involved in ccRCC pathogenesis. To the best of our knowledge, these pathogenic factors have not previously been linked to kidney cancer. 
